XTL Biopharmaceuticals Ltd. (XTLB) - Form 20-F Summary
Business Context and Reporting Period
This Annual Report on Form 20-F covers the fiscal year ended December 31, 2025. XTL Biopharmaceuticals Ltd. is an Israeli company incorporated in 1993, historically focused on biopharmaceutical development. The company's business profile underwent significant transformation during the reporting period and subsequent events:
- Discontinued Operations: The company lost effective control of its 2024 acquisition, The Social Proxy Ltd. (an AI data company), effective January 1, 2025, due to a dispute with former shareholders. Consequently, The Social Proxy was deconsolidated and classified as a discontinued operation. In February 2026, an Israeli court ordered The Social Proxy's liquidation.
- Strategic Pivot: In June 2026 (subsequent to the reporting period), XTL completed the acquisition of Psyga Bio Ltd., a biotechnology company focused on psychedelic and functional mushroom therapeutics. This marks a shift from legacy assets to early-stage psychedelic drug development.
- Listing Status: The company faced multiple Nasdaq delisting notices regarding minimum bid price, stockholders' equity, and "public shell" status. A Nasdaq Hearings Panel granted an exception for continued listing in May 2026, contingent on completing the Psyga Bio transaction and demonstrating compliance by June 30, 2026.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (USD '000) | 2024 (USD '000) |
|---|---|---|
| Revenues | 0 | 0 (Continuing Ops) |
| Operating Loss | (1,688) | (775) |
| Net Loss (Continuing Ops) | (759) | 240 |
| Loss from Discontinued Ops | (6,210) | (1,267) |
| Total Net Loss | (6,969) | (1,027) |
| Cash and Cash Equivalents | 76 | 371 |
| Total Assets | 166 | 8,550 |
| Total Shareholders' Equity | (254) | 5,435 |
| Accumulated Deficit | (165,632) | (159,009) |
Note: The 2024 comparative figures for revenues and operating loss reflect continuing operations only, as The Social Proxy results were reclassified to discontinued operations.
Material Changes vs. Prior Period
- Deconsolidation Impact: The most significant change was the deconsolidation of The Social Proxy. This resulted in a $6.2 million loss from discontinued operations in 2025, primarily due to the write-off of goodwill ($3.2M) and intangible assets ($3.4M) associated with the subsidiary, plus a bad debt loss of $308,000 on loans extended to the subsidiary.
- Asset Reduction: Total assets plummeted from $8.55 million in 2024 to $166,000 in 2025, driven by the removal of The Social Proxy's assets and the sale of the company's entire investment in InterCure Ltd. ($777,000 proceeds).
- Equity Deficit: Shareholders' equity turned negative, moving from a positive $5.4 million in 2024 to a deficit of $254,000 in 2025, largely due to the accumulated losses and the write-down of the discontinued operation.
- Non-Cash Gains: The company recorded significant non-cash finance income of $1.1 million in 2025 related to the revaluation of warrants, which partially offset the operating losses.
Guidance, Outlook, Risks, and Contingencies
Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. With only $76,000 in cash as of year-end and no revenue from continuing operations, the company requires additional financing to fund operations and the Psyga Bio integration.
Outlook and Strategy:
- Psyga Bio Integration: The company's future relies on the successful integration of Psyga Bio, which holds a pipeline of seven Phase 2a clinical trials for psychedelic therapeutics. The acquisition was completed in June 2026 via a share issuance representing 33.36% of XTL's capital.
- Capital Raise: A private placement of up to $1.5 million was approved by shareholders in June 2026 to support the Psyga transaction and operations.
- Legacy Assets: The company has ceased active development of its legacy hCDR1 asset (sublicensed to Biossil in 2025) and rHuEPO.
Key Risks:
- Delisting: Continued risk of delisting from Nasdaq if compliance conditions (equity levels, timely filing) are not met.
- Regulatory Uncertainty: Psyga Bio's products involve Schedule I controlled substances (psilocybin, ibogaine), facing complex FDA and DEA regulatory pathways.
- Geopolitical: Operations in Israel expose the company to risks from regional military conflicts (Israel-Hamas, Israel-Iran).
- Internal Controls: The company identified a material weakness in internal controls over financial reporting, specifically regarding the timely filing of periodic reports.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $1.5 million private placement proceeds to fund Psyga Bio's clinical trials and XTL's operating expenses beyond the next 12 months.
- Nasdaq Compliance: Confirm the company has met the June 30, 2026 deadline to demonstrate compliance with Nasdaq listing rules (specifically stockholders' equity and filing requirements).
- Psyga Bio Valuation: Assess the fair value of the Psyga Bio acquisition and the potential dilution impact of the milestone-based share issuances (up to an additional 25% of capital).
- Going Concern Resolution: Monitor for any additional equity or debt financing announcements required to resolve the "substantial doubt" regarding the company's viability.
- Internal Control Remediation: Review the company's plan to remediate the material weakness in internal controls over financial reporting.